Kaya Turan, Kahraman Berke, Bazarov Nurgeldi, Toker Alperen S, Celik Ayse, Cigdem Sadik, Gunduz Esra
.
Clin Invest Med. 2016 Dec 1;39(6):27493.
MYC is a transcription factor coding gene that is believed to control 15% of the genes in the entire human genome. The central role of c-MYC in cancer pathogenesis makes it a major therapeutic target in field of anticancer agent development.
We targeted the acetyl-lysine binding modules or bromodomains, which are associated with c-MYC transcriptional activation.
Sequence specific inhibition of BET bromodomains with small hairpin RNAs (shRNAs) resulted in cessation of cellular proliferation in different cancer cell lines. Unlike previous studies on inhibition of bromodomains with selective small-molecule inhibitors, our study revealed the significant role of BET bromodomains in solid tumours and also highlighted the ease of RNA interference (RNAi) methodology for inhibition of bromodomain translation.
The degree of influence of BET bromodomain inhibition on proliferation in five cancer cell lines established it as the major target in malignancies characterized by activation of c-MYC.
MYC是一种转录因子编码基因,据信它控制着整个人类基因组中15%的基因。c-MYC在癌症发病机制中的核心作用使其成为抗癌药物开发领域的主要治疗靶点。
我们靶向与c-MYC转录激活相关的乙酰赖氨酸结合模块或溴结构域。
用小发夹RNA(shRNA)对BET溴结构域进行序列特异性抑制导致不同癌细胞系的细胞增殖停止。与先前关于用选择性小分子抑制剂抑制溴结构域的研究不同,我们的研究揭示了BET溴结构域在实体瘤中的重要作用,还突出了RNA干扰(RNAi)方法抑制溴结构域翻译的简便性。
BET溴结构域抑制对五种癌细胞系增殖的影响程度确立了它作为以c-MYC激活为特征的恶性肿瘤的主要靶点。